Fonarow GC, et al. - A study using the Markov model in patients with very high-risk atherosclerotic cardiovascular disease, reflecting the 2018 ACC/AHA guideline definition and using the new evolocumab list price, the researchers intended to present an updated cost-effectiveness analysis of evolocumab added to standard background therapy in comparison to standard background therapy alone. Strong association of evolocumab with both increased costs and improved outcomes when added to standard background therapy was found with an incremental cost ranged from $22 228 to $3411. Hence, in patients with very high-risk atherosclerotic cardiovascular disease as defined by the 2018 ACC/AHA guideline, the addition of evolocumab to standard background therapy met accepted cost-effectiveness thresholds across a range of baseline cardiovascular event rates at its current list price.